{"id":"NCT02005666","sponsor":"Zydus Lifesciences Limited","briefTitle":"To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel","officialTitle":"A Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel (of Cadila Healthcare Limited, India) Versus DUAC® Gel (of Stiefel Laboratories, USA) Versus Placebo (Vehicle Gel) in the Ratio of 2:2:1 Respectively, in Patients With Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2016-09-28","completion":"2016-09-28","firstPosted":"2013-12-09","resultsPosted":"2020-09-14","lastUpdate":"2020-10-14"},"enrollment":850,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel","otherNames":["1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of CHL"]},{"type":"DRUG","name":"DUAC® Gel","otherNames":["DUAC® Gel (of Stiefel Laboratories"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo (Vehicle Gel)"]}],"arms":[{"label":"Test-Cadila healthcare limited","type":"EXPERIMENTAL"},{"label":"Reference","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study.\n\nThe main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate 1.2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC® Gel of Stiefel Laboratories)in the ratio of 2:2:1 of Test drug, Reference drug and Placebo respectively.\n\nTotal study duration will be for a period of 78 days which includes treatment duration of 77 days.\n\n850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria mentioned in the protocol.","primaryOutcome":{"measure":"Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions.","timeFrame":"week 11","effectByArm":[{"arm":"Test-Cadila Healthcare Limited","deltaMin":-67.6,"sd":28.39},{"arm":"Reference-DUAC® Gel","deltaMin":-71.3,"sd":25.98},{"arm":"Placebo","deltaMin":-51.9,"sd":33.99}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States","India"]},"refs":{"pmids":["2804254","19911678"],"seeAlso":["http://www.aafp.org/afp/2004/0501/p2123.html","http://www.jahonline.org/article/S1054-139X(08)00271-1/abstract","http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16509","http://www.ncbi.nlm.nih.gov/pmc/articles/PMC172501","http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050741s019lbl.pdf","http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071292.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":338},"commonTop":["Headache","Nasopharyngitis","Application site dryness","Pyrexia","Application site pruritus"]}}